1. 331PRibociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3. (23rd October 2018) Authors: Jerusalem, G; Fasching, P A; Martín, M; Pivot, X; Petrakova, K; Bianchi, G V; Nusch, A; Sonke, G S; De La Cruz Merino, L; Vagnon, E; Alam, J; Kong, O; Chandiwana, D; De Laurentiis, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1428PTesting for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German registry CRISP (AIO-TRK-0315). (23rd October 2018) Authors: Griesinger, F; Eberhardt, W E E; Nusch, A; Reiser, M; Bernhardt, C; Marschner, N; Jaenicke, M; Fleitz, A; Spring, L; Sahlmann, J; Karatas, A; Hipper, A; Weichert, W; Rittmeyer, A; Bischoff, H; Waller, C; Thomas, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗